Monte Rosa Therapeutics (GLUE) Capital Expenditures Growth (5y) (2025 - 2026)

Monte Rosa Therapeutics (GLUE) Capital Expenditures Growth (5y) (2025 - 2026) Analysis & Trends

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-
2	Nanobiotix	1,912.79 Bn	1,912.72 Bn	-
3	Akari Therapeutics	1,045.06 Bn	1,045.06 Bn	-
4	BeOne Medicines	470.64 Bn	465.84 Bn	1.35 Bn
5	Vertex Pharmaceuticals	122.91 Bn	115.67 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	70.07 Bn	61.31 Bn	3.31 Bn
7	Belite Bio	62.77 Bn	62.77 Bn	-
8	Argenx Se	56.21 Bn	51.02 Bn	1.41 Bn
9	Revolution Medicines	37.60 Bn	37.60 Bn	-
10	Monte Rosa Therapeutics	2.27 Bn	1.60 Bn	-

Download Data